Advertisement
Screener

AMNEAL PHARMACEUTICALS, INC. (AMRX) Increase (Decrease) in Prepaid Expense and Other Assets

AMNEAL PHARMACEUTICALS, INC. Increase (Decrease) in Prepaid Expense and Other Assets

AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Increase (Decrease) in Prepaid Expense and Other Assets of $24.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06

  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $10.75M, a 13.13% increase year-over-year.
  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $13.40M, a 2512.09% increase year-over-year.
  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$1.01M.
  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $10.16M.
  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $19.16M, a 1898.23% increase from fiscal 2024.
  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $959.00K.
  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$37.81M.
  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$9.88M, a 144.96% decline from fiscal 2021.
Period endIncrease (Decrease) in Prepaid Expense and Other Assets 3 monthIncrease (Decrease) in Prepaid Expense and Other Assets 6 monthIncrease (Decrease) in Prepaid Expense and Other Assets 6 month as first filedIncrease (Decrease) in Prepaid Expense and Other Assets 9 monthIncrease (Decrease) in Prepaid Expense and Other Assets 12 monthIncrease (Decrease) in Prepaid Expense and Other Assets 12 month as first filed
2026-06-30$10.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$24.15M
10-Q · filed 2026-08-06
$23.14M
derived: sum of 3 quarters · filed 2026-08-06
$33.30M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$13.40M
10-Q · filed 2026-05-07
$12.39M
derived: sum of 2 quarters · filed 2026-05-07
$22.55M
derived: sum of 3 quarters · filed 2026-05-07
$32.05M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$1.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$9.15M
derived: sum of 2 quarters · filed 2026-02-27
$18.65M
derived: sum of 3 quarters · filed 2026-08-06
$19.16M
10-K · filed 2026-02-27
2025-09-30$10.16M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$19.66M
derived: sum of 2 quarters · filed 2026-08-06
$20.17M
10-Q · filed 2025-11-06
$19.05M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$9.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$10.02M
10-Q · filed 2026-08-06
$8.89M
derived: sum of 3 quarters · filed 2026-08-06
$2.56M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$513.00K
10-Q · filed 2026-05-07
-$610.00K
derived: sum of 2 quarters · filed 2026-05-07
-$6.95M
derived: sum of 3 quarters · filed 2026-05-07
-$10.24M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$1.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
-$7.46M
derived: sum of 2 quarters · filed 2026-02-27
-$10.75M
derived: sum of 3 quarters · filed 2026-02-27
$959.00K
10-K · filed 2026-02-27
2024-09-30-$6.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$9.63M
derived: sum of 2 quarters · filed 2025-11-06
$2.08M
10-Q · filed 2025-11-06
-$10.92M
derived: sum of 4 quarters · filed 2026-02-27
2024-06-30-$3.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$8.42M
10-Q · filed 2025-08-07
-$4.59M
derived: sum of 3 quarters · filed 2026-02-27
$2.50M
derived: sum of 4 quarters · filed 2026-02-27
2024-03-31$11.71M
10-Q · filed 2025-05-07
-$1.30M
derived: sum of 2 quarters · filed 2026-02-27
$5.79M
derived: sum of 3 quarters · filed 2026-02-27
$3.05M
derived: sum of 4 quarters · filed 2026-02-27
2023-12-31-$13.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
-$5.92M
derived: sum of 2 quarters · filed 2026-02-27
-$8.65M
derived: sum of 3 quarters · filed 2026-02-27
-$37.81M
10-K · filed 2026-02-27
2023-09-30$7.09M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$4.35M
derived: sum of 2 quarters · filed 2024-11-12
-$24.81M
10-Q · filed 2024-11-12
-$69.07M
derived: sum of 4 quarters · filed 2025-02-28
2023-06-30-$2.74M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09
-$31.90M
10-Q · filed 2024-08-09
-$76.16M
derived: sum of 3 quarters · filed 2025-02-28
-$161.53M
derived: sum of 4 quarters · filed 2025-02-28
2023-03-31-$29.16M
10-Q · filed 2024-05-08
-$73.42M
derived: sum of 2 quarters · filed 2025-02-28
-$158.79M
derived: sum of 3 quarters · filed 2025-02-28
-$43.47M
derived: sum of 4 quarters · filed 2025-02-28
2022-12-31-$44.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28
-$129.63M
derived: sum of 2 quarters · filed 2025-02-28
-$14.30M
derived: sum of 3 quarters · filed 2025-02-28
-$9.88M
10-K · filed 2025-02-28
2022-09-30-$85.37M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$29.96M
derived: sum of 2 quarters · filed 2023-11-09
$34.38M
10-Q · filed 2023-11-09
$28.87M
derived: sum of 4 quarters · filed 2024-03-14
2022-06-30$115.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
$119.75M
10-Q · filed 2023-08-08
$114.23M
derived: sum of 3 quarters · filed 2024-03-14
$117.74M
derived: sum of 4 quarters · filed 2024-03-14
2022-03-31$4.42M
10-Q · filed 2023-05-09
-$1.09M
derived: sum of 2 quarters · filed 2024-03-14
$2.42M
derived: sum of 3 quarters · filed 2024-03-14
$27.01M
derived: sum of 4 quarters · filed 2024-03-14
2021-12-31-$5.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
-$2.01M
derived: sum of 2 quarters · filed 2024-03-14
$22.58M
derived: sum of 3 quarters · filed 2024-03-14
$21.98M
10-K · filed 2024-03-14
2021-09-30$3.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
$28.09M
derived: sum of 2 quarters · filed 2022-11-07
$27.49M
10-Q · filed 2022-11-07
$11.82M
derived: sum of 4 quarters · filed 2023-03-03
2021-06-30$24.59M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
$23.99M
10-Q · filed 2022-08-08
$8.31M
derived: sum of 3 quarters · filed 2023-03-03
-$552.00K
derived: sum of 4 quarters · filed 2023-03-03
2021-03-31-$602.00K
10-Q · filed 2022-05-06
-$16.28M
derived: sum of 2 quarters · filed 2023-03-03
-$25.14M
derived: sum of 3 quarters · filed 2023-03-03
-$60.30M
derived: sum of 4 quarters · filed 2023-03-03
2020-12-31-$15.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03
-$24.54M
derived: sum of 2 quarters · filed 2023-03-03
-$59.70M
derived: sum of 3 quarters · filed 2023-03-03
-$33.31M
10-K · filed 2023-03-03
2020-09-30-$8.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
-$44.02M
derived: sum of 2 quarters · filed 2021-11-08
-$17.64M
10-Q · filed 2021-11-08
-$15.25M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30-$35.16M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
-$8.77M
10-Q · filed 2021-08-09
-$6.39M
derived: sum of 3 quarters · filed 2022-03-01
-$19.03M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$26.38M
10-Q · filed 2021-05-07
$28.77M
derived: sum of 2 quarters · filed 2022-03-01
$16.13M
derived: sum of 3 quarters · filed 2022-03-01
$10.17M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$2.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
-$10.26M
derived: sum of 2 quarters · filed 2022-03-01
-$16.21M
derived: sum of 3 quarters · filed 2022-03-01
-$38.87M
10-K · filed 2022-03-01
2019-09-30-$12.64M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
-$18.60M
derived: sum of 2 quarters · filed 2020-11-06
-$41.26M
10-Q · filed 2020-11-06
-$40.23M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30-$5.96M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
-$28.61M
10-Q · filed 2020-08-06
-$27.59M
derived: sum of 3 quarters · filed 2021-03-01
-$42.50M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31-$22.66M
10-Q · filed 2020-05-11
-$21.63M
derived: sum of 2 quarters · filed 2021-03-01
-$36.54M
derived: sum of 3 quarters · filed 2021-03-01
-$29.94M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31$1.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
-$13.88M
derived: sum of 2 quarters · filed 2021-03-01
-$7.28M
derived: sum of 3 quarters · filed 2021-03-01
-$8.78M
10-K · filed 2021-03-01
-$19.20M
10-K · filed 2019-03-01
2018-09-30-$14.91M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
-$8.31M
derived: sum of 2 quarters · filed 2019-11-07
-$9.80M
10-Q · filed 2019-11-07
-$3.10M
derived: sum of 4 quarters · filed 2020-03-02
2018-06-30$6.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05
$5.11M
10-Q · filed 2019-08-05
-$711.00K
10-Q · filed 2018-08-09
$11.81M
derived: sum of 3 quarters · filed 2020-03-02
$24.46M
derived: sum of 4 quarters · filed 2020-03-02
2018-03-31-$1.49M
10-Q · filed 2019-05-09
$5.21M
derived: sum of 2 quarters · filed 2020-03-02
$17.86M
derived: sum of 3 quarters · filed 2020-03-02
2017-12-31$6.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
$19.35M
derived: sum of 2 quarters · filed 2020-03-02
$25.30M
10-K · filed 2020-03-02
2017-09-30$12.65M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
$18.60M
10-Q · filed 2018-11-07
2017-06-30$5.96M
10-Q · filed 2018-08-09
2016-12-31-$2.04M
10-K · filed 2019-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Liquidia Corp (LQDA)United States$6.347B51.23
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
Alkermes plc. (ALKS)$6.844B132.74
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07